Literature DB >> 19191903

Regulation of different inflammatory diseases by impacting the mevalonate pathway.

Robert Zeiser1, Kristina Maas, Sawsan Youssef, Christoph Dürr, Lawrence Steinman, Robert S Negrin.   

Abstract

The 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) interfere with the mevalonate pathway. While initially developed for their lipid-lowering properties, statins have been extensively investigated with respect to their impact on autoantigen and alloantigen driven immune responses. Mechanistically it was shown that statins modify immune responses on several levels, including effects on dendritic cells, endothelial cells, macrophages, B cells and T cells. Several lines of evidence suggest that statins act in a disease-specific manner and are not effective in each immune disorder. This review discusses possible modes of action of statins in modulating immunity towards autoantigens and alloantigens.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19191903      PMCID： PMC2678178          DOI： 10.1111/j.1365-2567.2008.03011.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


  64 in total

1.  Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.

Authors:  Jon A Kobashigawa; Jaime D Moriguchi; Hillel Laks; Liane Wener; Antoine Hage; Michele A Hamilton; Greg Cogert; Angela Marquez; Maria E Vassilakis; Jignesh Patel; Lawrence Yeatman
Journal:  J Heart Lung Transplant       Date:  2005-11       Impact factor: 10.247

Review 2.  Impact of HMG-CoA reductase inhibition on brain pathology.

Authors:  Frauke Zipp; Sonia Waiczies; Orhan Aktas; Oliver Neuhaus; Bernhard Hemmer; Burkhard Schraven; Robert Nitsch; Hans-Peter Hartung
Journal:  Trends Pharmacol Sci       Date:  2007-06-15       Impact factor: 14.819

3.  Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.

Authors:  Shaul Atar; Yumei Ye; Yu Lin; Sheldon Y Freeberg; Shawn P Nishi; Salvatore Rosanio; Ming-He Huang; Barry F Uretsky; Jose R Perez-Polo; Yochai Birnbaum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-12-09       Impact factor: 4.733

4.  The effects of atorvastatin on gluten-induced intestinal T cell responses in coeliac disease.

Authors:  M Ráki; O Molberg; S Tollefsen; K E A Lundin; L M Sollid
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

5.  A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease.

Authors:  Akiko Hori; Yoshinobu Kanda; Susumu Goyama; Yasushi Onishi; Yukiko Komeno; Kinuko Mitani; Yukiko Kishi; Seishi Ogawa; Osamu Imataki; Shigeru Chiba; Rie Kojima; Tamae Hamaki; Michiyo Sakiyama; Masahiro Kami; Atsushi Makimoto; Ryuji Tanosaki; Yoichi Takaue; Hisamaru Hirai
Journal:  Transplantation       Date:  2005-02-15       Impact factor: 4.939

6.  Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios.

Authors:  Hiroko Kanda; Kazuhiro Yokota; Chieko Kohno; Tetsuji Sawada; Kojiro Sato; Masao Yamaguchi; Yoshinori Komagata; Kota Shimada; Kazuhiko Yamamoto; Toshihide Mimura
Journal:  Mod Rheumatol       Date:  2007-10-19       Impact factor: 3.023

7.  Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Authors:  David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

Authors:  Olaf Stüve; Sawsan Youssef; Martin S Weber; Stefan Nessler; Hans-Christian von Büdingen; Bernhard Hemmer; Thomas Prod'homme; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

9.  Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.

Authors:  G A Ferreira; T P Navarro; R W Telles; L E C Andrade; E I Sato
Journal:  Rheumatology (Oxford)       Date:  2007-08-10       Impact factor: 7.580

10.  Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.

Authors:  Shannon E Dunn; Sawsan Youssef; Matthew J Goldstein; Thomas Prod'homme; Martin S Weber; Scott S Zamvil; Lawrence Steinman
Journal:  J Exp Med       Date:  2006-02-13       Impact factor: 14.307
View more
  12 in total

1.  Statins and influenza: can we move forward?

Authors:  Edward E Walsh
Journal:  J Infect Dis       Date:  2011-12-13       Impact factor: 5.226

2.  Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.

Authors:  Hong Wang; Ghanashyam Sarikonda; Kia-Joo Puan; Yoshimasa Tanaka; Ju Feng; José-Luis Giner; Rong Cao; Jukka Mönkkönen; Eric Oldfield; Craig T Morita
Journal:  J Immunol       Date:  2011-10-19       Impact factor: 5.422

3.  The beneficial effects of statin therapy may not apply to all forms of crescentic glomerulonephritis.

Authors:  Bahjat Al-Ani; Hamad Al Nuaimi; Caroline Savage
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 4.  Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.

Authors:  Hugo Ribeiro Zanetti; Leonardo Roever; Alexandre Gonçalves; Elmiro Santos Resende
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

5.  Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Marcello Rotta; Barry E Storer; Rainer Storb; Paul J Martin; Mary E D Flowers; Miwa S Vernon; Amanda Peffer; David G Maloney; H Joachim Deeg; Brenda M Sandmaier; Frederick R Appelbaum; Marco Mielcarek
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

Review 6.  Immune modulatory effects of statins.

Authors:  Robert Zeiser
Journal:  Immunology       Date:  2018-02-20       Impact factor: 7.397

7.  Statins Disrupt Macrophage Rac1 Regulation Leading to Increased Atherosclerotic Plaque Calcification.

Authors:  Abigail Healy; Joshua M Berus; Jared L Christensen; Cadence Lee; Chris Mantsounga; Willie Dong; Jerome P Watts; Maen Assali; Nicolle Ceneri; Rachael Nilson; Jade Neverson; Wen-Chih Wu; Gaurav Choudhary; Alan R Morrison
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-30       Impact factor: 8.311

8.  Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.

Authors:  Marcello Rotta; Barry E Storer; Rainer F Storb; Paul J Martin; Shelly Heimfeld; Amanda Peffer; David G Maloney; H Joachim Deeg; Brenda M Sandmaier; Frederick R Appelbaum; Marco Mielcarek
Journal:  Blood       Date:  2009-12-04       Impact factor: 22.113

Review 9.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

10.  Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties.

Authors:  Ning Zhao; Qian Dong; Cheng Qian; Sen Li; Qiong-Feng Wu; Dan Ding; Jing Li; Bin-Bin Wang; Ke-fang Guo; Jiang-jiao Xie; Xiang Cheng; Yu-Hua Liao; Yi-Mei Du
Journal:  Sci Rep       Date:  2015-11-30       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.